nirogacestat,al102
springworks therapeutics,ayala pharmaceuticalsceuticals,novartis
['nirogacestat', 'al102', '$swtx', '$ayla']
$ayla al102's ph2/3 interim data in esmo 2022: 1/9 patients had pr, others were stable disease at week 16. $swtx nirogacestat's ph3 data: pfs's hazard ratio 0.29, and orr 41%, of which cr 7%. nda will be submitted by the end of 2022.
Jot some of my thoughts | Mainly healthcare related | Not Investment Advice